


AMENDMENTS TO THE CLAIMS

1. (Currently Amended) A pharmaceutical composition comprising the following ingredients (A) and (B):

Ingredient (A): An alkyl ether derivative represented by the following formula:




wherein R^1 represents a ~~substituted or unsubstituted heterocyclic benzothienyl group which may be substituted with a group selected from a halogen atom, an alkyl group, and a phenyl group~~; R^2 represents a hydrogen atom ~~or a hydroxyl group~~; R^3 and R^4 , ~~which may be the same or different~~, each represents a ~~substituted or unsubstituted an alkyl group, or~~ R^3 and R^4 , taken conjointly with the nitrogen atom to which R^3 and R^4 are linked, form a ~~substituted or unsubstituted cyclic amino group an azetidine ring~~; m represents an integer of 1 to 5; and n represents an integer of 1 to 6 ~~2 to 3~~; or a salt thereof,

Ingredient (B): A compound ~~selected from the group consisting of Donepezil and Tacrine having an acetylcholine esterase inhibitory activity or a salt thereof, which is different from ingredient (A)~~.

2. – 3. (Canceled)

4. (Currently Amended) A method of preparing a medicament comprising combining the following ingredients (A) and (B),

Ingredient (A): An alkyl ether derivative represented by the following formula:



wherein R¹ represents a substituted or unsubstituted heterocyclic benzothienyl group which may be substituted with a group selected from a halogen atom, an alkyl group, and a phenyl group; R² represents a hydrogen atom or a hydroxyl group; R³ and R⁴, which may be the same or different, each represents a substituted or unsubstituted alkyl group, or R³ and R⁴, taken conjointly with the nitrogen atom to which R³ and R⁴ are linked, form a substituted or unsubstituted cyclic amino group an azetidine ring; m represents an integer of 1 to 5; and n represents an integer of 1 to 6 2 to 3; or a salt thereof,

Ingredient (B): A compound selected from the group consisting of Donepezil and Tacrine having an acetylcholine esterase inhibitory activity or a salt thereof, which is different from ingredient (A).

5. – 6. (Cancelled)

7. (Currently Amended) A pharmaceutical composition as claimed in claim 1 wherein the pharmaceutical composition is administered to a patient to improve cerebral function treat Alzheimer's disease.

8. (Currently Amended) A method as claimed in claim 4 further comprising administering the medicament to a patient in order to ~~improve cerebral function treat~~ Alzheimer's disease.

9. (New) The pharmaceutical composition as claimed in claim 1, wherein said ingredient (A) is 1-[3-(2-(1-benzothiophen-5-yl)ethoxy]propyl]-3-azetidinol·or a salt thereof.

10. (New) The pharmaceutical composition as claimed in claim 1, wherein said ingredient (A) is 1-[3-(2-(1-benzothiophen-5-yl)ethoxy]propyl]-3-azetidinol·maleate.

11. (New) The method as claimed in claim 4, wherein said ingredient (A) is 1-[3-(2-(1-benzothiophen-5-yl)ethoxy]propyl]-3-azetidinol·or a salt thereof.

12. (New) The method as claimed in claim 4, wherein said ingredient (A) is 1-[3-(2-(1-benzothiophen-5-yl)ethoxy]propyl]-3-azetidinol·maleate.